Search Clinical Trials
The BU-CTSI is a center of expertise providing tools, services and resources to clinical investigators, maximizing the impact of discoveries & speeding the translation of research into improved patient care
180 matching studies
Study is registered in ResearchMatch  Sponsor Condition of Interest |
|---|
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
CRISPR Therapeutics
SLE (Systemic Lupus)
Lupus Erythematosus, Systemic
Lupus Nephritis
Systemic Sclerosis
Inflammatory Myopathy, Idiopathic
This is a single-arm, open-label, multicenter, ascending dose Phase 1 study evaluating
the safety and preliminary efficacy of CTX112 in adult subjects with refractory
autoimmune diseases, including active systemic lupus erythematosus (SLE), systemic
sclerosis (SSc), or idiopathic inflammatory myopa1 expand
This is a single-arm, open-label, multicenter, ascending dose Phase 1 study evaluating the safety and preliminary efficacy of CTX112 in adult subjects with refractory autoimmune diseases, including active systemic lupus erythematosus (SLE), systemic sclerosis (SSc), or idiopathic inflammatory myopathy (IIM). Type: Interventional Start Date: Mar 2025 |
|
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sc1
Novartis Pharmaceuticals
Scleroderma, Diffuse
The purpose of this study is to evaluate the efficacy, safety and tolerability of
rapcabtagene autoleucel (administered once following lymphodepletion) in participants
with severe refractory diffuse cutaneous systemic sclerosis relative to rituximab. expand
The purpose of this study is to evaluate the efficacy, safety and tolerability of rapcabtagene autoleucel (administered once following lymphodepletion) in participants with severe refractory diffuse cutaneous systemic sclerosis relative to rituximab. Type: Interventional Start Date: Oct 2024 |